GlassScriptPhysician profile
Emily D Moore
NPI 1871001412
$10,489.19
in general payments reported to CMS, 2019-2025
48 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,668 · 2022: $2,325 · 2023: $2,042 · 2024: $2,554 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,470 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,469.96 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,710.51 | 2021-2025 | |
| Sk Life Science, INC. | $667.71 | 2021-2025 | |
| Ucb, INC. | $607.97 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Neurocrine Biosciences, INC. | $599.08 | 2022-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $519.90 | 2021-2025 | Ultomiris |
| Mdd US Operations, LLC | $444.76 | 2022-2024 | Gocovri, Gocovri, Apokyn |
| Kyowa Kirin, INC. | $385.63 | 2021-2024 | Nourianz |
| Eisai INC. | $375.80 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $360.18 | 2023-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $340.56 | 2021-2025 | Austedo Xr, Uzedy |
| Catalyst Pharmaceuticals, INC. | $265.81 | 2023-2025 | Firdapse |
| Neurelis, INC. | $257.13 | 2022-2025 | Valtoco |
| Lundbeck LLC | $255.85 | 2021-2025 | Vyepti, Rexulti |
| Csl Behring | $239.64 | 2023 | Hizentra |
| Pfizer INC. | $226.59 | 2023-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $226.33 | 2021-2025 | Kisunla, Amyvid |
| Supernus Pharmaceuticals, INC. | $219.02 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $209.61 | 2021-2022 | |
| Amgen INC. | $195.57 | 2021-2025 | Uplizna |
| Acorda Therapeutics, INC | $195.34 | 2021-2023 | Inbrija |
| Sunovion Pharmaceuticals INC. | $189.72 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $189.34 | 2023-2024 | Aptiom |
| Acadia Pharmaceuticals INC | $157.48 | 2021-2025 | Nuplazid, Daybue |
| Merz Pharmaceuticals, LLC | $148.64 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Emd Serono, INC. | $146.18 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $119.63 | 2021-2025 | Crexont |
| Biohaven Pharmaceuticals, INC. | $116.68 | 2021 | |
| Biogen, INC. | $107.93 | 2025 | Leqembi, Tysabri, Vumerity |
| Impel Pharmaceuticals INC. | $98.34 | 2023 | Trudhesa |
| Grifols USA, LLC | $85.31 | 2023-2025 | Gamunex-C |
| Biohaven Pharmaceutical Holding Company LTD. | $83.25 | 2022 | |
| Axsome Therapeutics, INC. | $81.18 | 2025 | Symbravo |
| Argenx US, INC. | $73.21 | 2022-2025 | Vyvgart |
| Tanabe Pharma America, INC. | $66.97 | 2021-2024 | |
| Ge Healthcare | $63.95 | 2021-2022 | |
| Allergan, INC. | $60.31 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $58.66 | 2021 | |
| Cycle Pharmaceuticals INC | $58.08 | 2025 | Tascenso Odt, Bafiertam |
| Harmony Biosciences LLC | $52.63 | 2022-2023 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $48.67 | 2023-2024 | Hyqvia |
| Upsher-Smith Laboratories LLC | $29.04 | 2022 | |
| Mindray Ds USA, INC. | $27.78 | 2025 | Patient Monitor, Na Electrode,Indirect,International |
| Janssen Biotech, INC. | $25.82 | 2025 | |
| Silk Road Medical, INC. | $25.02 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Jazz Pharmaceuticals INC. | $22.80 | 2022 | |
| Scilex Pharmaceuticals INC. | $20.37 | 2023 | Ztlido |
| Medtronic, INC. | $15.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.